Nissan has issued a recall of more than 800,000 vehicles in the U.S. and Canada after engine issues were reported.
The impacted models include Nissan Rogues made in 2014 through 2020 and Rogue Sports made between 2017 and 2022.
The issue lies in the jackknife folding key. The automaker said that when it is partially opened and inserted into the ignition, a driver can inadvertently hit the key fob and shut the engine off. A loss of power, non-functioning breaks, and airbags not deploying then would be possible, according to Nissan.
"Over time the internal pivot of the jackknife key may weaken and the key could unlock and rotate downwards," the company said in its voluntary recall notice.
Nissan does not yet have a fix for the problem. This month, the automaker will send out letters to customers informing them that no other object should be attached to the key fob. They will receive a second notice to receive repairs once a remedy for the problem has been found.
So far, no incidents as a result of the key problem have not been reported.
We spoke with a farmer about how tariffs, trade policy, drought, and packer consolidation are reshaping the economics of American ranching and farming.
John Serafini, CEO of Hawkeye 360, breaks down the company’s 87% revenue growth, global demand for space-based intelligence and plans to scale its business.
Dan Niles, Founder and Portfolio Manager at Niles Investment Management, breaks down NVIDIA’s blowout earnings, 70% growth forecast and AI spending boom.
Edwin Cywinski, CEO of SunScout Holding Limited, explains how solar-powered robotic mowers are transforming lawn care and the company’s plans to scale.
Nathan Bomey, Business Reporter at Axios and author of The Axios Closer newsletter, explains why Wall Street is turning NVIDIA’s AI chips into financial assets.
Jamie Siminoff, Founder and Chief Inventor of Ring, explains the company’s new TAKE encryption standard and its push to put privacy and video data control first
Xavier Martinez, News Associate at The Wall Street Journal, breaks down Moderna’s mRNA ambitions, its pipeline beyond COVID-19 and the challenges ahead.
